Confronto

Pramlintid vs. VK2735

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

151126-32-8

nessun dato

Peso molecolare

3949.4 g/mol

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Pramlintid	VK2735
Germania	Non approvato	Non approvato
Stati Uniti	Su prescrizione	Non approvato

Voci complete

Frequently asked questions

What is the difference between Pramlintid and VK2735?: Pramlintid is classified as "Metabolico", while VK2735 is classified as "Metabolico". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pramlintid or VK2735?: The highest available evidence level is "RCT sull'uomo" for Pramlintid and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pramlintid and VK2735 in Germany and the United States?: Germania: Pramlintid — Non approvato, VK2735 — Non approvato. Stati Uniti: Pramlintid — Su prescrizione, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Pramlintid

VK2735

Germania

Non approvato

Stati Uniti

Su prescrizione

Non approvato

Frequently asked questions

What is the difference between Pramlintid and VK2735?

Pramlintid is classified as "Metabolico", while VK2735 is classified as "Metabolico". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pramlintid or VK2735?

The highest available evidence level is "RCT sull'uomo" for Pramlintid and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pramlintid and VK2735 in Germany and the United States?

Germania: Pramlintid — Non approvato, VK2735 — Non approvato. Stati Uniti: Pramlintid — Su prescrizione, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.